Economic evaluation of dapagliflozin added to standard therapy in chronic heart failure in Argentina: a cost-utility analysis
- DOI
- 10.1016/j.lana.2026.101571
- Published
- 2026-10
- Container
- The Lancet Regional Health - Americas
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.lana.2026.101571,
title = {Economic evaluation of dapagliflozin added to standard therapy in chronic heart failure in Argentina: a cost-utility analysis},
author = {Javier Santiago Araujo and Francisco Moioni and Diego Sebastián Novielli and Germán Andrés Jelusic and Sofía Inés Lucini and Jeremías Augusto Zabalo and José Alberto Spala and María Celeste Piervincenzi},
year = {2026},
journal = {The Lancet Regional Health - Americas},
doi = {10.1016/j.lana.2026.101571},
url = {https://doi.org/10.1016/j.lana.2026.101571}
}RIS
TY - JOUR TI - Economic evaluation of dapagliflozin added to standard therapy in chronic heart failure in Argentina: a cost-utility analysis AU - Javier Santiago Araujo AU - Francisco Moioni AU - Diego Sebastián Novielli AU - Germán Andrés Jelusic AU - Sofía Inés Lucini AU - Jeremías Augusto Zabalo AU - José Alberto Spala AU - María Celeste Piervincenzi PY - 2026 JO - The Lancet Regional Health - Americas DO - 10.1016/j.lana.2026.101571 UR - https://doi.org/10.1016/j.lana.2026.101571 ER -
APA
Araujo, J. S., Moioni, F., Novielli, D. S., Jelusic, G. A., Lucini, S. I., Zabalo, J. A., Spala, J. A., & Piervincenzi, M. C. (2026). Economic evaluation of dapagliflozin added to standard therapy in chronic heart failure in Argentina: a cost-utility analysis. The Lancet Regional Health - Americas. https://doi.org/10.1016/j.lana.2026.101571
Source records
- crossref · retrieved 2026-09-26T08:20:11.882Z